632 related articles for article (PubMed ID: 34359926)
1. Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity.
Rand U; Kupke SY; Shkarlet H; Hein MD; Hirsch T; Marichal-Gallardo P; Cicin-Sain L; Reichl U; Bruder D
Cells; 2021 Jul; 10(7):. PubMed ID: 34359926
[TBL] [Abstract][Full Text] [Related]
2. Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral Therapy.
Pelz L; Rüdiger D; Dogra T; Alnaji FG; Genzel Y; Brooke CB; Kupke SY; Reichl U
J Virol; 2021 Nov; 95(24):e0117421. PubMed ID: 34550771
[TBL] [Abstract][Full Text] [Related]
3. Broad-Spectrum Antiviral Activity of Influenza A Defective Interfering Particles against Respiratory Syncytial, Yellow Fever, and Zika Virus Replication In Vitro.
Pelz L; Piagnani E; Marsall P; Wynserski N; Hein MD; Marichal-Gallardo P; Kupke SY; Reichl U
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766278
[TBL] [Abstract][Full Text] [Related]
4. Defective Interfering Particles with Broad-Acting Antiviral Activity for Dengue, Zika, Yellow Fever, Respiratory Syncytial and SARS-CoV-2 Virus Infection.
Lin MH; Li D; Tang B; Li L; Suhrbier A; Harrich D
Microbiol Spectr; 2022 Dec; 10(6):e0394922. PubMed ID: 36445148
[TBL] [Abstract][Full Text] [Related]
5. Defective Interfering Particles of Influenza Virus and Their Characteristics, Impacts, and Use in Vaccines and Antiviral Strategies: A Systematic Review.
Wu M; Zhou E; Sheng R; Fu X; Li J; Jiang C; Su W
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560777
[TBL] [Abstract][Full Text] [Related]
6. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
7. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
8. Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance.
Chaturvedi S; Vasen G; Pablo M; Chen X; Beutler N; Kumar A; Tanner E; Illouz S; Rahgoshay D; Burnett J; Holguin L; Chen PY; Ndjamen B; Ott M; Rodick R; Rogers T; Smith DM; Weinberger LS
Cell; 2021 Dec; 184(25):6022-6036.e18. PubMed ID: 34838159
[TBL] [Abstract][Full Text] [Related]
9. Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta.
Fröba M; Große M; Setz C; Rauch P; Auth J; Spanaus L; Münch J; Ruetalo N; Schindler M; Morokutti-Kurz M; Graf P; Prieschl-Grassauer E; Grassauer A; Schubert U
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947999
[TBL] [Abstract][Full Text] [Related]
10. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
11. Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles.
Hein MD; Arora P; Marichal-Gallardo P; Winkler M; Genzel Y; Pöhlmann S; Schughart K; Kupke SY; Reichl U
BMC Biol; 2021 May; 19(1):91. PubMed ID: 33941189
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor.
Cao N; Cai Y; Huang X; Jiang H; Huang Z; Xing L; Lu L; Jiang S; Xu W
mBio; 2024 May; 15(5):e0074124. PubMed ID: 38587427
[TBL] [Abstract][Full Text] [Related]
13. Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.
Schuhenn J; Meister TL; Todt D; Bracht T; Schork K; Billaud JN; Elsner C; Heinen N; Karakoese Z; Haid S; Kumar S; Brunotte L; Eisenacher M; Di Y; Lew J; Falzarano D; Chen J; Yuan Z; Pietschmann T; Wiegmann B; Uebner H; Taube C; Le-Trilling VTK; Trilling M; Krawczyk A; Ludwig S; Sitek B; Steinmann E; Dittmer U; Lavender KJ; Sutter K; Pfaender S
Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35131898
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of SARS-CoV-2 by type I and type III interferons.
Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F
J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093
[TBL] [Abstract][Full Text] [Related]
15. Broad-Spectrum Antiviral Activity of 3D8, a Nucleic Acid-Hydrolyzing Single-Chain Variable Fragment (scFv), Targeting SARS-CoV-2 and Multiple Coronaviruses In Vitro.
Lee G; Budhathoki S; Lee GY; Oh KJ; Ham YK; Kim YJ; Lim YR; Hoang PT; Lee Y; Lim SW; Kim JM; Cho S; Kim TH; Song JW; Lee S; Kim WK
Viruses; 2021 Apr; 13(4):. PubMed ID: 33918914
[TBL] [Abstract][Full Text] [Related]
16. Production of antiviral "OP7 chimera" defective interfering particles free of infectious virus.
Pelz L; Dogra T; Marichal-Gallardo P; Hein MD; Hemissi G; Kupke SY; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2024 Dec; 108(1):97. PubMed ID: 38229300
[TBL] [Abstract][Full Text] [Related]
17. Viral Interference During Influenza A-SARS-CoV-2 Coinfection of the Human Airway Epithelium and Reversal by Oseltamivir.
Cheemarla NR; Watkins TA; Mihaylova VT; Foxman EF
J Infect Dis; 2024 May; 229(5):1430-1434. PubMed ID: 37722683
[TBL] [Abstract][Full Text] [Related]
18. Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus.
Al-Beltagi S; Preda CA; Goulding LV; James J; Pu J; Skinner P; Jiang Z; Wang BL; Yang J; Banyard AC; Mellits KH; Gershkovich P; Hayes CJ; Nguyen-Van-Tam J; Brown IH; Liu J; Chang KC
Viruses; 2021 Feb; 13(2):. PubMed ID: 33546185
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
20. A Novel Type of Influenza A Virus-Derived Defective Interfering Particle with Nucleotide Substitutions in Its Genome.
Kupke SY; Riedel D; Frensing T; Zmora P; Reichl U
J Virol; 2019 Feb; 93(4):. PubMed ID: 30463972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
